Ilyang Pharmaceutical Co.,Ltd (KRX:007570)

South Korea flag South Korea · Delayed Price · Currency is KRW
11,400
+220 (1.97%)
At close: Apr 2, 2026
Market Cap204.34B -22.0%
Revenue (ttm)272.42B +1.4%
Net Income6.90B -23.6%
EPS375.00 -23.5%
Shares Out17.92M
PE Ratio30.40
Forward PEn/a
Dividend150.00 (1.34%)
Ex-Dividend DateDec 29, 2025
Volume308,157
Average Volume104,540
Open11,290
Previous Close11,180
Day's Range11,250 - 12,650
52-Week Range9,540 - 16,240
Beta0.58
RSI33.91
Earnings DateMay 13, 2026

About KRX:007570

Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, antifungal drugs, anti-inflammatory analgesic drugs, insecticides, and vaccines; and health drinks, daily food, supplements, health food, cosmetics, and be... [Read more]

Sector Healthcare
Founded 1946
Employees 666
Stock Exchange Korea Stock Exchange
Ticker Symbol 007570
Full Company Profile

Financial Performance

In 2025, KRX:007570's revenue was 272.42 billion, an increase of 1.39% compared to the previous year's 268.68 billion. Earnings were 6.90 billion, a decrease of -23.55%.

Financial Statements